(S)-3,5-DHPG, group I mGlu agonist (ab120007)
Key features and details
- Selective group I mGlu agonist
- CAS Number: 162870-29-3
- Soluble in water to 50 mM
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
(S)-3,5-DHPG, group I mGlu agonist -
製品の詳細
Selective group I mGlu agonist -
生理活性の詳細
Selective group I mGlu agonist.
Also available in simple stock solutions (ab144484) - add 1 ml of water to get an exact, ready-to-use concentration. -
CAS 番号
162870-29-3 -
構造式
製品の特性
-
体系名
(S)-3,5-Dihydroxyphenylglycine -
分子量
183.16 -
分子式
C8H9NO4 -
PubChem 登録番号
443586 -
保存方法
Store at -20°C. Store In the Dark. Store under desiccating conditions. This product is air and light sensitive and impurities can occur as a result of air oxidation or due to metabolism by microbes. -
溶解性
Soluble in water to 50 mM -
使用に関する注意
This compound is also unstable in alkaline solution when it rapidly forms a brown colouration it is therefore recommended that alkaline is not used to dissolve this compound.
We recommend stock solutions are made up in water, aliquoted immediately and stored at -20°C. They should be used within one week.Refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
Oc1cc(cc(O)c1)[C@H](N)C(=O)O -
由来
Synthetic
-
研究分野
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab120007の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Functional Studies |
Use at an assay dependent concentration.
|
特記事項 |
---|
Functional Studies
Use at an assay dependent concentration. |
画像
-
2D chemical structure image of ab120007, (S)-3,5-DHPG, group I mGlu agonist
-
SK-N-SH cells were incubated at 37°C for 30 minutes with vehicle control (0 µM) and different concentrations of (S)-3,5-DHPG (ab120007). Increased expression of CREB (phospho S133) in SK-N-SH cells correlates with an increase (S)-3,5-DHPG concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 20 µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 3% milk before being incubated with ab32096 at 1/500 dilution and ab32515 at 1 µg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (29)
ab120007 は 29 報の論文で使用されています。
- Špirková A et al. Glutamate can act as a signaling molecule in mouse preimplantation embryos†. Biol Reprod 107:916-927 (2022). PubMed: 35746896
- Serra I et al. Ca2+-modulated photoactivatable imaging reveals neuron-astrocyte glutamatergic circuitries within the nucleus accumbens. Nat Commun 13:5272 (2022). PubMed: 36071061
- Fernandes G et al. Correction of amygdalar dysfunction in a rat model of fragile X syndrome. Cell Rep 37:109805 (2021). PubMed: 34644573
- Redolfi N et al. A New Transgenic Mouse Line for Imaging Mitochondrial Calcium Signals. Function (Oxf) 2:zqab012 (2021). PubMed: 35330679
- Subrahmanyam R et al. Reciprocal regulation of spontaneous synaptic vesicle fusion by Fragile X mental retardation protein and group I metabotropic glutamate receptors. J Neurochem 158:1094-1109 (2021). PubMed: 34327719